Amicus is proving rare disease profits can scale
- Amicus reached its first quarter of positive GAAP net income in Q3 2025, with $17.3 million of net income.
- Galafold is still the base of the business, with $138.3 million of Q3 2025 revenue and 12% constant-currency growth.
- Pombiliti and Opfolda are the main growth bet, with $30.7 million of Q3 2025 revenue and 42% constant-currency growth.
- Management reiterated 2025 total revenue growth guidance of 15% to 22% at constant exchange rates.
- The next big pipeline watch is DMX-200, where the Phase 3 ACTION3 trial was over 90% enrolled in Q3 2025.
Profit proof changes the story
Amicus has crossed an important line. In Q3 2025, it reported its first quarter of positive GAAP net income. GAAP means the standard accounting rule set public companies use. Net income was $17.3 million, or $0.06 per share, compared with a loss in the year-earlier quarter.
The bull case is now simpler. Galafold keeps growing in Fabry disease, while Pombiliti and Opfolda are adding faster growth in Pompe disease. Management also kept its 2025 guidance in place: total revenue growth of 15% to 22%, Galafold growth of 10% to 15%, and Pombiliti and Opfolda growth of 50% to 65%, all at constant exchange rates.
The bear case is weaker than it was after Q1 2025, when Amicus cut the Pombiliti and Opfolda growth guide because of timing delays in new European markets. Q2 and Q3 showed stronger demand, more markets coming online, and record new commercial demand for both product lines.
This is still biotech. A launch can slow, payers can push back on price, and Phase 3 trial data can disappoint. The stock story now depends less on proving Amicus can survive and more on proving growth and profits can last into 2026 and beyond.
Two drugs fund the pipeline
Amicus makes money by selling rare disease treatments around the world. The business is concentrated in two commercial product lines: Galafold for Fabry disease and Pombiliti with Opfolda for late-onset Pompe disease.
The model works best when more diagnosed patients start therapy, more untreated patients are found, and insurers agree to pay. These are small patient groups, so each new start matters more than it would for a common disease drug.
Galafold is the larger product today. Pombiliti and Opfolda are smaller but growing much faster. Management says both products had their strongest quarter ever for new commercial demand in Q3 2025.
The company is also adding a late-stage pipeline option through DMX-200 for FSGS, a rare kidney disease. That adds upside if the trial works, but it also brings clinical and regulatory risk back into the story.
Fabry base, Pompe growth, kidney option
Galafold
Galafold is an oral precision medicine for Fabry disease patients with amenable mutations. It produced $138.3 million of revenue in Q3 2025 and remains the core revenue base.
Pombiliti
Pombiliti is the enzyme part of Amicus's two-component Pompe therapy. It is used with Opfolda for adults with late-onset Pompe disease and is in a global launch.
Opfolda
Opfolda is paired with Pombiliti to help the therapy work in late-onset Pompe disease. Together, Pombiliti and Opfolda produced $30.7 million of Q3 2025 revenue.
DMX-200
DMX-200 is a Phase 3 drug candidate for FSGS, a rare kidney disease. Amicus has U.S. commercialization rights through its Dimerix licensing deal.
Revenue still leans on Galafold
Mix is based on Q3 2025 product revenue: Galafold at $138.3 million and Pombiliti and Opfolda at $30.7 million. The company is still concentrated in Galafold, but Pompe is growing faster.
What can still go wrong
Pompe launch slows after the rebound
High impact · Medium oddsPombiliti and Opfolda are the key growth driver. Q3 2025 helped answer fears from the Q1 guide cut, but the launch still needs steady new patient starts and more country launches. If growth fades, the market may stop treating Amicus like a durable growth story.
Payers limit access or price
High impact · Medium oddsRare disease drugs often need country-by-country pricing and reimbursement approval. Amicus has made progress, including reimbursement in 15 countries for Pombiliti and Opfolda by Q3 2025, but access can still be slow or narrower than expected.
Competition wins patient switches
Medium impact · Medium oddsThe Pompe market has other treatment options. Amicus needs doctors and patients to believe Pombiliti and Opfolda are worth switching to. Real-world evidence and long-term study updates are important because they help support that choice.
Galafold growth runs out of easy patients
Medium impact · Medium oddsGalafold depends on finding Fabry patients with amenable mutations and keeping them on therapy. The drug still posted record demand in Q3 2025, but growth gets harder as market share rises in mature countries.
DMX-200 trial fails or slips
Medium impact · Medium oddsDMX-200 could give Amicus a new rare disease market, but it is still an investigational drug. Phase 3 studies can fail even when the medical need is high. A delay or poor result would hurt the pipeline part of the thesis.
In one breath
Is Amicus Therapeutics profitable now?
Amicus reported positive GAAP net income in Q3 2025 for the first time. Management also reiterated its expectation for positive GAAP net income in the second half of 2025.
What is Amicus Therapeutics' biggest product?
Galafold is the biggest product today. It generated $138.3 million of Q3 2025 revenue, compared with $30.7 million for Pombiliti and Opfolda.
Why does Pombiliti and Opfolda matter so much?
It is the faster-growing commercial product line and the main driver of the next leg of growth. Management reiterated 2025 constant-currency growth guidance of 50% to 65% for Pombiliti and Opfolda.
What is the next major catalyst for FOLD?
The main near-term checks are full-year 2025 results, second-half GAAP profitability, and full enrollment of the DMX-200 Phase 3 ACTION3 trial. A possible pediatric label expansion filing for Pombiliti and Opfolda is also expected in mid-2026.